Celldex Therapeutics, Inc. (CLDX)
-NasdaqGS 15.44 
0.04(0.26%) 9:47AM EDT - Nasdaq Real Time Price
| Prev Close: | 15.40 |
|---|
| Open: | N/A |
|---|
| Bid: | 15.50 x 1000 |
|---|
| Ask: | 15.59 x 400 |
|---|
| 1y Target Est: | 16.86 |
|---|
| Beta: | 2.94 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 15.21 - 15.60 |
|---|
| 52wk Range: | 4.36 - 16.48 |
|---|
| Volume: | 97,651 |
|---|
| Avg Vol (3m): | 1,433,670 |
|---|
| Market Cap: | 1.25B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.99 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Celldex Turning Into A Compelling Immunotherapy Biotechat Seeking Alpha(Wed 4:05AM EDT)
- [$$] Can Green Mountain Coffee and 4 Biotechs Climb?at Barrons.com(Mon, Jun 17)
- Immunotherapy: Four Companies on the Verge of Cancer-Treatment Breakthroughsat Minyanville(Mon, Jun 17)
- A Trio of Cancer Immunotherapy Innovatorsat Motley Fool(Sat, Jun 15)
- Good And Bad Breast Cancer Drugsat Motley Fool(Fri, Jun 14)
- [$$] Buying the Celldex Storyat Barrons.com(Thu, Jun 13)
- CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial StatemeEDGAR Online(Thu, Jun 13)
- 3 longs and 3 shorts to watchat MarketWatch(Wed, Jun 12)
- 4 Stocks Spiking on Unusual Volumeat TheStreet(Mon, Jun 10)
- Options Change Hands On Diamond Foods Ahead Of Earningsat Seeking Alpha(Mon, Jun 10)
- Trade bets Celldex will hold big gainsoptionMONSTER(Mon, Jun 10)
- A Promising Platform for Cancer Immunotherapyat Motley Fool(Sat, Jun 8)
- 5 Stocks To Watch For Gains Next Weekat Seeking Alpha(Fri, Jun 7)
- Clovis Among Top Small-Cap Biotech Picks By Legendary Fund Managers In Q1/2013at Seeking Alpha(Tue, Jun 4)
- 4 Stocks Spiking on Big Volumeat TheStreet(Mon, Jun 3)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 111.37 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.97 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States.
View More